Skip to content
Open access

Diagnostic evaluation and clinical utility of C-MoKa for prenatal genetic testing.

Jul 2026 · Journal of Translational Medicine · 0 citations
Medicine

TL;DR

Evaluated diagnostic performance and clinical utility of C-MoKa in prenatal diagnosis and its technical concordance with standard of care testings in prenatal diagnosis demonstrate that C-MoKa is a highly effective and reliable method for prenatal diagnosis, exhibiting high concordance with SOC techniques.

Abstract

Background

C-MoKa (Chromosome Conformation-based Karyotyping) is a novel 3D genome mapping platform, that enables simultaneous detection of structural variations (SVs), aneuploidies, copy number variations (CNVs), and uniparental disomy (UPD) in a single test. However, its performance in routine prenatal diagnosis is still unexplored. This study aimed to comprehensively evaluate the diagnostic performance and clinical utility of C-MoKa in prenatal diagnosis, and to assess its technical concordance with standard of care (SOC) testings in prenatal diagnosis.

Methods

A two-phase study was designed. In phase 1, 56 retrospective participants with known chromosomal abnormalities (CAs) were recruited, and C-MoKa was performed on their cultured amniotic fluid (AF) samples. Concordance between C-MoKa and known CAs was analyzed. In phase 2, a prospective cohort of 208 participants for prenatal diagnosis were recruited. Samples underwent C-MoKa and karyotyping (KT), with parallel chromosomal microarray analysis (CMA) or improved whole-exome sequencing (iWES). In our study, supplementary copy number probes were enhanced in iWES detection, which could provide ~ 100 kb resolution across the genome, thus either CMA or iWES platform employed was used to assess the CNV detection. Diagnostic yields and concordance were evaluated, and the discordance of SVs and CNVs were further validated by fluorescence in situ hybridization (FISH) and CNV-seq, respectively.

Results

In the retrospective cohort with known CAs, C-MoKa achieved a 94.6% (53/56) diagnostic yield and 92.8% (52/56) concordance with KT + CNV. In the prospective cohort, its diagnostic yield was 21.2% (44/208), higher than KT (12.5%, 26/208) and CNV (18.3%, 38/208). The diagnostic yield (22.6%, 47/208) was achieved when CNV platform and C-MoKa were used together. C-MoKa exhibited concordance rates of 89.4% (186/208) with KT, 89.9% (187/208) with CNV, and 90.4% (188/208) with KT + CNV. Two SVs identified by C-MoKa but missed by KT were successfully determined by FISH, and five samples with additional CNVs identified by C-MoKa were consistently detected by CNV-seq.

Conclusions

Our findings demonstrate that C-MoKa is a highly effective and reliable method for prenatal diagnosis, exhibiting high concordance with SOC techniques. Compared to the conventional application of "KT + CNV" in prenatal setting, the combined use of CNV and C-MoKa appears to maximize the diagnostic yield.

Read PDF

Similar papers

Open access Aug 2026

The Application Value of Chromosome Microarray Analysis in Prenatal Diagnosis of Clinically Relevant Copy Number Variations in Fetuses

Objective Exploring the clinical application value of chromosome microarray analysis (CMA) technology in detecting clinically relevant copy number variations (CNVs) in fetuses and evaluating its efficacy in prenatal diagnosis. Methods A retrospective analysis was conducted on 2860 pregnant women undergoing prenatal dia...

Huifang Liu, Wei Wang, Zhaoling Zhu et al. · 0 citations
Open access Aug 2026

Combined Application Value of Chromosome Karyotype Analysis and Chromosomal Microarray Analysis (CMA) in Prenatal Diagnosis

Objective: Chromosome karyotype analysis is the gold standard for prenatal diagnosis yet carries multiple limitations. Chromosomal microarray analysis (CMA) can overcome these drawbacks to a certain extent. This study aims to evaluate the clinical application value of combined chromosome karyotype analysis and CMA in t...

Y.-Y. Zhou, L. Huang, Q.-E. Zhang et al. · 0 citations
Aug 2026

Prenatal Whole-exome Sequencing in a Russian Clinical Cohort: Diagnostic Yield, Indications, and Spectrum of Molecular Findings

Prenatal whole-exome sequencing demonstrates high clinical utility in the diagnosis of fetal monogenic disorders and shows the greatest effectiveness in fetuses with structural anomalies and in families at high genetic risk.

E. Kudryavtseva, I. Kanivets, V. Udalova et al. · 0 citations
Open access Aug 2026

Detection and Clinical Significance of Chromosomal Mosaicism in Prenatal Diagnosis: A Retrospective Study From a Prenatal Diagnosis Center

ABSTRACT Background To evaluate the detection capabilities of prenatal screening and diagnostic methods for fetal chromosomal mosaicism and analyze associated pregnancy outcomes. Methods This retrospective study included 79 cases of fetal chromosomal mosaicism identified by karyotyping among 8106 women undergoing prena...

Yu-Heng Pei, Xiaojin Luo, Jianghua Ran et al. · 0 citations
Review Aug 2026

Prenatal diagnosis of large regions of homozygosity (ROH) in non-imprinted areas.

OBJECTIVE The aim of the present study was to analyze prenatal diagnostic indications, diagnostic results, and pregnancy outcomes associated with fetuses exhibiting large regions of homozygosity (ROH) in non-imprinted regions, ultimately providing a reference for related prenatal diagnosis and genetic counseling. MET...

Qianzhu Jiang, Haihua Yu, Lin Yuan · 0 citations
Open access Aug 2026

Complementary Diagnostic Roles of Non-Invasive Prenatal Testing, Chromosomal Microarray Analysis, and Karyotyping in 14,011 High-Risk Pregnancies: A Retrospective Cohort Study with Combined Analyses

Background/Objectives: Prenatal chromosomal assessment can benefit from the complementary use of non-invasive prenatal testing (NIPT), chromosomal microarray analysis (CMA), and karyotyping because each test provides different information. Methods: We retrospectively analyzed 14,011 fetus-specific amniotic fluid cases...

Seungyeon Lee, Suhng-Wook Kim, Eunhee Lee et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.